A股異動 | 廣生堂(300436.SZ)收漲4.33% 乙肝治療創新藥獲Ⅱ期臨牀試驗倫理委員會批件
格隆匯2月25日丨廣生堂(300436.SZ)午後直線拉昇,最終收報39.8元,漲4.33%,全天成交4億元,最新市值63億元。廣生堂今日午間公佈,公司於近日獲得吉林大學第一醫院倫理委員會出具的關於同意開展“一項評價GST-HG141聯合富馬酸丙酚替諾福韋片(TAF)在慢性乙型肝炎(CHB)患者中的有效性與安全性的多中心、隨機、雙盲、安慰劑對照的II期臨牀研究”的審查意見,標誌着公司乙肝治療創新藥GST-HG141的II期臨牀試驗方案已經通過PI臨牀單位審核確定。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.